Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Tonix Pharmaceuticals Holding (TNXP) EBIT Margin (2023 - 2025)

Tonix Pharmaceuticals Holding (TNXP) has 3 years of EBIT Margin data on record, last reported at 1005.08% in Q3 2025.

  • For Q3 2025, EBIT Margin fell 45391.0% year-over-year to 1005.08%; the TTM value through Sep 2025 reached 969.97%, up 91435.0%, while the annual FY2024 figure was 1354.28%, 16966.0% up from the prior year.
  • EBIT Margin reached 1005.08% in Q3 2025 per TNXP's latest filing, up from 1416.22% in the prior quarter.
  • Across five years, EBIT Margin topped out at 551.17% in Q3 2024 and bottomed at 3501.63% in Q2 2024.
  • Average EBIT Margin over 3 years is 1154.43%, with a median of 860.23% recorded in 2024.
  • Peak YoY movement for EBIT Margin: tumbled -268329bps in 2024, then soared 208541bps in 2025.
  • A 3-year view of EBIT Margin shows it stood at 705.62% in 2023, then fell by -23bps to 870.64% in 2024, then dropped by -15bps to 1005.08% in 2025.
  • Per Business Quant database, its latest 3 readings for EBIT Margin were 1005.08% in Q3 2025, 1416.22% in Q2 2025, and 660.93% in Q1 2025.